150 related articles for article (PubMed ID: 37722697)
1. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
Febres-Aldana CA; Fanaroff R; Offin M; Zauderer MG; Sauter JL; Yang SR; Ladanyi M
Annu Rev Pathol; 2024 Jan; 19():11-42. PubMed ID: 37722697
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
4. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
Paajanen J; Bueno R; De Rienzo A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
[TBL] [Abstract][Full Text] [Related]
5. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
Vivero M; Bueno R; Chirieac LR
Mod Pathol; 2018 Jan; 31(1):122-131. PubMed ID: 28884745
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
12. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
13. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
16. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
17. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract][Full Text] [Related]
18. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural neoplasm with both differentiation of epithelioid mesothelioma and squamous-cell carcinoma, a rare phenomena.
Re A; Shersher D; Allen A; Schwarting R; Ren S
Diagn Cytopathol; 2021 Jun; 49(6):E234-E237. PubMed ID: 33347735
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
